Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Everolimus (Primary) ; Pazopanib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 08 Feb 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 08 Feb 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2019.
- 07 Jun 2016 Results of a retrospective analysis of pazopanib from 4 phase I trials in patients with advanced sarcoma (NCT01339871, NCT01430572, NCT01454804, NCT01454804) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.